Abstract
The diarylquinoline R207910 is in clinical development for tuberculosis treatment. The MIC(50) for 41 drug-susceptible and 44 multidrug-resistant Mycobacterium tuberculosis clinical isolates was 0.032 microg/ml. Out of 20 additional mycobacterial species, three were found to be naturally resistant to R207910 and were shown to exhibit a polymorphism in their atpE genes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Synthetase Complexes / antagonists & inhibitors*
-
ATP Synthetase Complexes / genetics
-
ATP Synthetase Complexes / metabolism
-
Amino Acid Sequence
-
Antitubercular Agents / pharmacology*
-
Diarylquinolines
-
Drug Resistance, Bacterial
-
Microbial Sensitivity Tests
-
Molecular Sequence Data
-
Mycobacterium tuberculosis / drug effects*
-
Mycobacterium tuberculosis / enzymology
-
Mycobacterium tuberculosis / genetics
-
Polymorphism, Genetic
-
Quinolines / pharmacology*
-
Sequence Homology, Amino Acid
Substances
-
Antitubercular Agents
-
Diarylquinolines
-
Quinolines
-
bedaquiline
-
ATP Synthetase Complexes